1.Study of Leshibao Capsule on gastrointestinal function
Shiwei CHEN ; Hong ZHENG ; Hongmin ZHANG ; Qizhong ZHENG ;
Chinese Traditional Patent Medicine 1992;0(04):-
Objective: To study the function of Leshibao Capsule (Radix Ginseng, Rhizoma Atractylodis, Sea cucumber, etc.) on stomach and intestines. Methods: Gastrointestinal function was measured by small intestine driving test, gastric juice quantity, pepsin activity and gastric emptying time. Results: Leshibao Capsule could increase gastric juice, enhance pepsin activity. It could adjust function of gastrointestine in two ways that showed gastrointestinal movement fasted by neostigmine and inhibited gastrointestinal movement slowed by diphenoxylate and morphine hydrochloride. Conclusion: Leshibao Capsule can adjust gastrointestinal function and facilitate digestive function.
2.Application of digital subtraction angiography-guided insertion of totally implantable venous access port in digestive system cancer patients
Yubin HU ; Mingzhi HAO ; Hailan LIN ; Qizhong CHEN ; Zhangxian CHEN ; Jianxiong ZHENG ; Jianbin CHEN ; Jing QING
Chinese Journal of Clinical Nutrition 2016;24(3):167-171
Objective To investigate the safety , feasibility , and clinical application value of digital sub-traction angiography ( DSA) -guided insertion of totally implantable venous access port ( TIVAP) in patients with digestive system cancer .Methods We retrospectively analyzed the data of 15 digestive system cancer patients who were inserted with TIVAP under DSA guidance between April 2013 and January 2016, recorded the TIVAP-related complications and indwelling time, and investigated the patients’satisfaction about TIVAP.Paired rank sum test was used for the differences in patients’quality of life before and after the insertion of TIVAP.Results Of the 15 digestive system cancer patients , operation success rate of TIVAP insertion was 100%, with the success rate of venipuncture on first attempt being 100%.The incidence of complication was 6.67% ( 1/15 ) , which was manifested as pull feeling at the neck occurring in the eighth month after insertion .The indwelling time of TIVAP was from 2 to 28 months, with a median value of 9 months.Patients’satisfaction rate of TIVAP was 86.67%(13/15).The proportion of patients with a good quality of life was 100%(15/15), statically signifi-cantly higher than that before the insertion [46.67%(7/15), Z=-3.416, P=0.000).Conclusions TIVAP insertion under DSA guidance in digestive system cancer patients is safe and feasible , with few complications and fair patient satisfaction .It may improve the patient ’s quality of life , worthy of clinical application .